TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease

Renee E., Vickman, La Tayia, Aaron-Brooks, Renyuan, Zhang, Nadia A., Lanman, Brittany, Lapin, Victoria, Gil, Max, Greenberg, Takeshi, Sasaki, Gregory M., Cresswell, Meaghan M., Broman, J. Sebastian, Paez, Jacqueline, Petkewicz, Pooja, Talaty, Brian T., Helfand, Alexander P., Glaser, Chi Hsiung, Wang, Omar E., Franco, Timothy L., Ratliff, Kent L., Nastiuk, Susan E., Crawford, Simon W., Hayward

Nature Communications | 2022

Autoimmune (AI) diseases can affect many organs; however, the prostate has not been considered to be a primary target of these systemic inflammatory processes. Here, we utilize medical record data, patient samples, and in vivo models to evaluate the impact of inflammation, as seen in AI diseases, on prostate tissue. Human and mouse tissues are used to examine whether systemic targeting of inflammation limits prostatic inflammation and hyperplasia. Evaluation of 112,152 medical records indicates that benign prostatic hyperplasia (BPH) prevalence is significantly higher among patients with AI diseases. Furthermore, treating these patients with tumor necrosis factor (TNF)-antagonists significantly decreases BPH incidence. Single-cell RNA-seq and in vitro assays suggest that macrophage-derived TNF stimulates BPH-derived fibroblast proliferation. TNF blockade significantly reduces epithelial hyperplasia, NFκB activation, and macrophage-mediated inflammation within prostate tissues. Together, these studies show that patients with AI diseases have a heightened susceptibility to BPH and that reducing inflammation with a therapeutic agent can suppress BPH.